Merck KGaA Seeks to Exit the Biosimilar Business
As a result of increasing competition, a smaller player (in the biosimilar field) is seeking to sell its nascent biosimilar business.
Insulin Glargine Update: Price Savings with Basaglar?
Insulin glargine biosimilars supposed to contribute 15% to total cost savings in overall biologic expenditures.
Last Year's Physician Survey: Barriers to Understanding Biosimilars
Survey shows education will be needed to convince physicians of the value of biosimilar agents.
Amgen's Amjevita at Risk for 2017 Launch
Amgen will await the outcome of its patent litigation with AbbVie before launching Amjevita.
House of Representatives Approves Bipartisan 21st Century Cures Legislation
